News

The head of global research and executive vice president of Atara Biotherapeutics discussed the development of ATA188.

The chief executive officer of Gamida Cell discussed upcoming research on 2 of their investigational agents, GDA-201 and omidubicel, for hematological malignancies.

Corlieve Therapeutics’ lead program, AMT-260, previously demonstrated proof-of-concept in preclinical studies of temporal lobe epilepsy.

Peter Riedell, MD, discussed the need for more research in mantle cell lymphoma and access to novel treatments, including CAR T-cell therapies.

Flexion Therapeutics believes that local administration of a gene therapy may not only improve pain management but potentially slow disease progression.

uniQure announced positive results from their phase 3 HOPE-B study of etranacogene dezaparvovec.

Newly published data continues to demonstrate Zolgensma's efficacy in presymptomatic and symptomatic SMA Type 1.

The chief executive officer of Gamida Cell discussed the company's novel approach to cell proliferation.

Jasper Therapeutics and Aruvant Sciences are studying the use of JSP191 used with ARU-1801 in patients with sickle cell disease.

C. Ola Landgren, MD, PhD, discussed the role of CAR T-cell therapies in multiple myeloma.

James Hoffman, MD, discussed the significance of the approval of ide-cel for patients with multiple myeloma.

Faith E. Davies, MD, discussed the potential of CAR T-cell therapies for the treatment of multiple myeloma.

At the 18-month follow-up, the CAR T-cell therapy led to early, deep, and durable responses with a manageable safety profile in patients with relapsed/refractory multiple myeloma.

LogicBio's Mariana Nacht, PhD, shares details of the company's novel capsid discovery platform and gene editing technology.

The news comes after CRISPR’s favorable data readouts in its sickle cell and beta thalassemia studies.

Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.

Results of the phase 1 portion of ZUMA-4 support continued investigation into the efficacy of KTE-X19 in pediatric patients with B-cell acute lymphoblastic leukemia.

The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed findings from the CARTITUDE studies.

Investigators find approach improved vision and visual fields in some patients.

Henry Chi Hang Fung, MD, from the Fox Chase Cancer Center, discusses axi-cel's potential in relapsed/refractory FL.

The chief scientific officer and chief medical officer at Eyevensys discuss the biotech company's pipeline and approach to gene therapy.

Detailed data from the phase 3 trial, including safety findings, which were in line with previous studies, will be presented at a future scientific meeting.

The allogeneic, cellularized scaffold product helps support autologous skin tissue regeneration in patients with thermal burns requiring surgical intervention.

Real-world data regarding the use of tisagenlecleucel and axicabtagene ciloleucel CAR T-cell therapy are reported at 2021 EHA.

A panel of lymphoma experts discussed 2 recently approved treatments that are providing hope to patients with relapsed or refractory follicular lymphoma.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

The chief medical officer of Eyevensys discussed the company’s work in developing sustained drug delivery systems.

The FDA has paused the clearance of new ofranergene obadenovec batches while it reviews chemistry, manufacturing, and controls at various source locations.

A comparative analysis of the ZUMA-5 and SCHOLAR-5 trials revealed improvements in outcomes over currently available therapies.

Previous research has suggested the efficacy of chimeric antigen receptor natural killer (CAR-NK) cells in hematological malignancies, and more recently, preclinical findings have raised the question of whether the type of treatment could be a viable, potentially more attractive option for solid tumors.